FIELD: chemistry.
SUBSTANCE: invention pertains to compounds with formula II or IIa and their pharmaceutically acceptable salts or esters, with inhibitor action on cathepsin K, in which R2 is chosen respectively from H, 2-ethylbutyl, isobutyl or 2,2-dimethylpropyl; or C3-C6cycloalkyl, predominantly cyclopropyl, cyclopentyl or cyclohexyl, R5' represents 4-methoxyphenyl, 4-(1-propylpiperidine-4-yl)phenyl, 4-(4-methylpiperazin-1-yl)phenyl, 4-[1-(2-methoxyethyl)piperidine-4-yl]phenyl, 4-(4-propylpiperazin-1-yl)phenyl, 3-[4-(4-methylpiperazin-1-yl)phenyl]propionyl, 3-[3-(4-methylpiperazin-1-yl)phenyl]propionyl, 4-(4-ethylpiperazin-1-yl)phenyl, 4-(4-isoporylpiperazin-1-yl)phenyl, 4-[4-(2-ethoxyethyl)piperazin-1-yl]phenyl, 4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl, 4-piperazin-1-yl phenyl, 4-[4-(tert-butyl ester of a carboxylic acid)piperazino-1-yl]phenyl, 3-(4-methylpiperazin-1-yl)phenyl, 3-(4-ethylpiperazin-1-yl)phenyl, 3-(4-isopropylpiperazin-1-yl)phenyl, 3-[4-(2-mthoxyethyl)piperazin-1-yl]phenyl, 3-[4-(2-ethoxyethyl)piperazin-1-yl]phenyl, 3-(2-pyrrolidine-1-yl ethoxy)phenyl, 3-(2-dimethylaminoethoxy)-4-methoxyphenyl, 4-dimethylaminomethylphenyl, 4-(4-methylpiperazin-1-yl methyl)phenyl, 4-[1-(2-methoxyethyl)piperazin-4-yl methyl]phenyl, 4-methoxy-3-(2-piperidine-1-yl ethoxy)phenyl, 3-[4-(4-ethylpiperazin-1-yl)phenyl]-2,2-dimethylpropionyl, 3-[4-(4-propylpiperazin-1-yl)phenyl]propionyl, 3-(4-pyrrolidine-1-yl phenyl)propionyl, 3-[3-(4-ethylpiperazin-1-yl)phenyl]-2,2-dimethylpropionyl, 3-{3-[4-(2-methoxyethyl)piperazin-1-yl]phenyl}-2,2-dimethylpropionyl, 3-(3-pyrrolidine-1-yl phenyl)propionyl, 2-[4-(4-methylpiperazin-1-yl)phenyl]isobutyl, 2-(4-methoxyphenyl)acetyl, 2-(3-methoxyphenyl)acetyl, 2-[4-(4-methylpiperazin-1-yl)phenyl]acetyl, 2-[4-(4-ethylpiperazin-1-yl)phenyl]acetyl, 2-[4-(4-isopropylpiperazin-1-yl)phenyl]acetyl, 2-(4-pyrrolidine-1-yl phenyl)acetyl, 2-[4-(2-diethylaminoethylamino)phenyl]isobutyl, 2-(4-pyrrolidine-1-yl phenyl)isobutyl. R5 "' and R6'" are respectively shown in the formula of invention.
EFFECT: cathepsin K inhibitor properties.
7 cl, 2 tbl, 109 ex
Title | Year | Author | Number |
---|---|---|---|
MEDICINAL COMPOUNDS | 2014 |
|
RU2691105C1 |
DERIVATIVES OF QUINAZOLINE | 2002 |
|
RU2302244C2 |
COMPOUND FOR DESTRUCTION OF ANDROGEN RECEPTOR AND ITS PHARMACEUTICAL USE THEREOF | 2021 |
|
RU2817356C1 |
BICYCLIC COMPOUND AND USE THEREOF FOR SUV39H2 INHIBITION | 2016 |
|
RU2729187C1 |
INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
NOVEL ARYLPIPERAZINYL COMPOUNDS | 2004 |
|
RU2339627C2 |
4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | 2005 |
|
RU2386628C2 |
NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | 2011 |
|
RU2585177C2 |
CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | 2008 |
|
RU2479584C2 |
10-AMINOALIPHATYLDIBENZ [b, f] OXEPINES, METHODS OF PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION | 1996 |
|
RU2160734C2 |
Authors
Dates
2008-06-10—Published
2002-08-29—Filed